Skip to main content

Table 5 Additional lipid efficiency outcomes following evolocumab treatments stratified by dosages versus placebo at 12-week follow-up

From: Safety and efficacy of anti-PCSK9 antibodies: a meta-analysis of 25 randomized, controlled trials

Endpoints

Evolocumab dosages

Mean Difference, % (95 % CI)

Test for overall effect

Number of studies

Number of individuals

Heterogeneity

Publication bias

Z

P value

Evolocumab

Placebo

I 2

P value

P_Begg

P_Egger

TC

420 mg Q4W

−36.66 (−38.93, −34.39)

31.60

0.000

6

539

825

38.0 %

0.153

1.000

0.980

140 mg Q2W

−40.48 (−45.33, −35.62)

16.35

0.000

4

456

730

85.3 %

0.000

0.734

0.552

HDL-C

420 mg Q4W

7.58 (5.69, 9.46)

7.89

0.000

9

688

1121

23.3 %

0.236

1.000

0.843

140 mg Q2W

6.90 (5.37, 8.43)

8.84

0.000

6

586

993

0.0 %

0.551

0.133

0.030

Non-HDL-C

420 mg Q4W

−52.11 (−55.07, −49.14)

34.42

0.000

8

672

1088

57.9 %

0.020

0.618

0.499

140 mg Q2W

−56.07 (−61.67, −50.47)

19.62

0.000

6

586

993

89.0 %

0.000

0.452

0.616

TC/HDL-C

420 mg Q4W

−41.26 (−45.65, −36.87)

18.43

0.000

6

317

374

64.7 %

0.015

0.566

0.302

140 mg Q2W

−44.85 (−49.11, −40.59)

20.64

0.000

4

229

285

63.6 %

0.041

0.089

0.126

VLDL-C

420 mg Q4W

−22.75 (−27.46, −18.04)

9.47

0.000

6

567

925

6.6 %

0.374

0.452

0.335

140 mg Q2W

−24.83 (−38.29, −11.38)

3.62

0.000

4

480

831

82.3 %

0.001

0.734

0.462

ApoB

420 mg Q4W

−45.14 (−49.16, −41.12)

22.00

0.000

9

688

1121

78.8 %

0.000

0.076

0.027

140 mg Q2W

−52.69 (−57.40, −47.98)

21.91

0.000

6

586

993

85.6 %

0.000

0.707

0.450

ApoA1

420 mg Q4W

5.17 (2.60, 7.73)

3.95

0.000

6

317

374

40.6 %

0.135

0.566

0.517

140 mg Q2W

6.26 (1.71, 10.82)

2.69

0.007

4

230

285

74.5 %

0.008

0.308

0.129

ApoB/ApoA1

420 mg Q4W

−48.06 (−52.70, −43.43)

20.32

0.000

7

395

527

72.4 %

0.001

0.649

0.351

140 mg Q2W

−53.68 (−57.77, −49.59)

25.74

0.000

5

305

438

65.8 %

0.020

0.806

0.500

TG

420 mg Q4W

−15.70 (−20.35, −11.05)

6.62

0.000

9

688

1121

42.5 %

0.084

0.118

0.030

140 mg Q2W

−17.35 (−23.50, −11.20)

5.53

0.000

6

586

993

59.8 %

0.029

1.000

0.039

Lp(a)

420 mg Q4W

−25.40 (−29.09, −21.70)

13.47

0.000

9

688

1121

47.1 %

0.057

1.000

0.626

140 mg Q2W

−32.39 (−38.92, −25.87)

9.73

0.000

6

586

993

79.3 %

0.000

1.000

0.819

PCSK9

420 mg Q4W

−44.04 (−53.90, −34.17)

8.75

0.000

6

540

908

85.2 %

0.000

0.452

0.473

140 mg Q2W

−60.92 (−83.94, −37.89)

5.18

0.000

2

132

188

92.9 %

0.000

1.000

NA

  1. ApoA1, apolipoprotein A1; ApoB, apolipoprotein B; ApoB/ApoA1, ratio of ApoB/ApoA1; CI, confidence interval; HDL-C, high-density lipoprotein (HDL) cholesterol; Lp(a), lipoprotein(a); NA, not applicable; Non-HDL-C, non-HDL cholesterol; PCSK9, proprotein convertase subtilisin/kexin type 9; TC, total cholesterol; TC/HDL-C, ratio of total cholesterol/HDL cholesterol; TG, triglycerides; VLDL-C, very low-density lipoprotein (VLDL) cholesterol